Assessing whether to perform a confirmatory randomized clinical trial

Journal of the National Cancer Institute

Volumn 88, Issue 22, 1996, Pages 1645-1651

  Parmar, Mahesh K B ^a   Ungerleider, Richard S ^b   Simon, Richard ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; LEVAMISOLE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SCREENING; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; BAYES THEOREM; CARCINOMA, NON-SMALL-CELL LUNG; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; LEVAMISOLE; LUNG NEOPLASMS; NEOPLASMS; OBSERVER VARIATION; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0029834102     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.22.1645     Document Type: Review

References (9)

1. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer [see comment citations in Medline]. N Engl J Med 1990;323:940-5.
2. Propert K, Kim K. Group sequential methods in multi-institutional cancer clinical trials. A case study. In: Peace KE, editor. Biopharmaceutical sequential statistical applications. New York: Marcel Dekker, Inc., 1992:133-53.
3. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial of regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
4. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic [see comment citation in Medline]. J Clin Oncol 1989;7:1447-56.
5. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma [see comment citations in Medline]. N Engl J Med 1990;322: 352-8.
6. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
7. George SL, Li C, Berry DA, Green MR. Stopping a clinical trial early: frequentist and Bayesian approaches to a CALGB trial in non-small-cell lung cancer. Stat Med 1994;13:1313-27.
8. Simon R. Randomized clinical trials and research strategy. Cancer Treat Rep 1982;66:1038-87.
9. Spiegelhalter DJ, Freedman LS, Parmar MK. Bayesian approaches to randomised trials. J R Stat Society [A] 1994;157:357-416.